DrugsNews.net

Drugs Xagena

Xagena Mappa
Medical Meeting
Onco News
XagenaNewsletter

The European Commission ( EC ) has approved Empliciti ( Elotuzumab ) plus Pomalidomide and low-dose Dexamethasone ( EPd ) for the treatment of adult patients with relapsed and refractory multiple myel ...


The Food and Drug Administration ( FDA ) has approved Nubeqa ( Darolutamide ) for non-metastatic castration-resistant prostate cancer. Approval was based on ARAMIS, a multicenter, double-blind, pla ...


The European Commission has approved Tecentriq ( Atezolizumab ) plus chemotherapy ( Abraxane [ Paclitaxel protein-bound particles for injectable suspension ( albumin-bound ); nab-Paclitaxel ] ) for th ...


The FDA ( Food and Drug Administration ) has granted accelerated approval to Xpovio ( Selinexor ) in combination with Dexamethasone for adult patients with relapsed or refractory multiple myeloma ( RR ...


The FDA ( Food and Drug Administration ) has approved Inrebic ( Fedratinib ) for adults with intermediate-2 or high-risk primary or secondary ( post-polycythemia vera or post-essential thrombocythemia ...


The FDA ( U.S. Food and Drug Administration ) has approved Rinvoq ( Upadacitinib ), a 15 mg, once-daily oral Janus kinase ( JAK ) inhibitor, for the treatment of adults with moderately to severely act ...


The FDA ( U.S. Food and Drug Administration ) has approved Emgality ( Galcanezumab-gnlm; Galcanezumab ) solution for injection for the treatment of episodic cluster headache in adults. Cluster hea ...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Rozlytrek ( Entrectinib ), a treatment for adult and adolescent patients whose cancers have the specific genetic defec ...


The FDA ( U.S. Food and Drug Administration ) has granted approval to Turalio ( Pexidartinib ) capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor ( TGCT ) asso ...


The European Commission has granted Marketing Authorisation for Dovato ( Dolutegravir / Lamivudine ) for the treatment of HIV-1 infection in adults and adolescents above 12 years of age weighing at le ...


The FDA ( U.S. Food and Drug Administration ) has approved Dupixent ( Dupilumab ) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis ( CRSwNP ) in adults whose disease i ...


The European Commission has approved Talzenna ( Talazoparib ), an oral poly (ADP-ribose) polymerase ( PARP ) inhibitor, as monotherapy for the treatment of adult patients with germline breast cancer s ...


The European Commission ( EC ) has approved Lynparza ( Olaparib ) as a 1st-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer. The licensed indication is as a maintenanc ...


The European Commission ( EC ) has granted conditional marketing authorization for Lorviqua ( Lorlatinib, available in the U.S., Canada and Japan under the brand name Lorbrena ), as a monotherapy for ...


The European Commission has approved Dupixent ( Dupilumab ) for use in adults and adolescents 12 years and older as an addon maintenance treatment for severe asthma with type 2 inflammation characteri ...